İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2023 · article

Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data

Dergi Balkan Medical Journal
ISSN1301-3149
YÖKSİS OpenAlex Açık erişim · diamond TR Index
Yıl2023
Atıf11OpenAlex
Yüzdelik%84,4
FWCI1,481,00 = dünya ortalaması
Scopus (SJR)Q3
WoS (JCR)Q2

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıBalkan Medical Journal
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

Background: Eltrombopag has an off-label indication for haematopoietic cell transplantation in patients experiencing delayed thrombocyte recovery and/or thrombocytopaenia. Aims: To present our centre’s experience of using this agent not only for post- haematopoietic cell transplantation thrombocytopaenia but also for poor graft functioning in the post-haematopoietic cell transplantation setting. Study Design: Retrospective cross-sectional study. Methods: Thirty-nine patients who had persistent cytopaenia following haematopoietic cell transplantation and treated with eltrombopag at our centre between October 2011 and December 2021 were retrospectively identified. During this period, 9 (23.1%) and 30 (76.9%) patients who underwent allogeneic transplantations, respectively, received eltrombopag. Results: = 0.001) with eltrombopag. No eltrombopag-related hepatotoxicity occurred; however, 1 (2.6%) patient failed to continue treatment because of two consecutive episodes of deep venous thrombosis. Six (15.4%) patients were unresponsive to eltrombopag and dependent on blood product transfusions. After a median time of 82 days, 61.5% of the patients discontinued eltrombopag successfully. Conclusion: The results confirmed that eltrombopag could provide a rapid, sustained response in patients with poor graft functioning after haematopoietic cell transplantation. This finding is essential given the high rate of non-relapse mortality caused by poor graft functioning after haematopoietic cell transplantation.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

11atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 6 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2024 Eltrombopag Treatment In Thrombocytopenia Following Hematopoietic STEM Cell Transplantation: A Multicenter Real-world ExperienceAtıf 5 · OpenAlex
  2. 2024 Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experienceAtıf 5 · OpenAlex
  3. 2024 Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experienceAtıf 5 · OpenAlex
  4. 2024 Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experienceAtıf 5 · OpenAlex
  5. 2023 Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft FunctionAtıf 4 · OpenAlex
  6. 2023 Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft FunctionAtıf 4 · OpenAlex

Yazarlar

15
  1. EKİN KIRCALI 1
  2. GÜLDANE CENGİZ SEVAL 2
  3. CEMALEDDİN ÖZTÜRK 3
  4. HÜLYA YİLMAZ TEKİNHATUN 4
  5. DERYA KOYUN 5
  6. SİNEM CİVRİZ BOZDAĞ 6
  7. SELAMİ KOÇAK TOPRAK 7
  8. PERVİN TOPÇUOĞLU 8
  9. ÖNDER ARSLAN 9
  10. MUHİT ÖZCAN ANKARA ÜNİVERSİTESİ 10
  11. TANER DEMİRER 11
  12. OSMAN İLHAN 12
  13. GÜNHAN GÜRMAN 13
  14. MERAL BEKSAÇ 14
  15. MELTEM YÜKSEL 15